Marc Tessier-Lavigne - 16 Mar 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/**Marc Tessier-Lavigne
Issuer symbol
REGN
Transactions as of
16 Mar 2022
Net transactions value
-$3,687,055
Form type
4
Filing time
18 Mar 2022, 16:05:21 UTC
Previous filing
05 Jan 2022
Next filing
23 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $1,631,537 +4,361 +192% $374.12 6,630 16 Mar 2022 Direct F1
transaction REGN Common Stock Sale $2,943,675 -4,361 -66% $675.00 2,269 16 Mar 2022 Direct F1
transaction REGN Common Stock Options Exercise $2,949,483 +7,830 +345% $376.69 10,099 17 Mar 2022 Direct F1
transaction REGN Common Stock Sale $5,324,400 -7,830 -78% $680.00 2,269 17 Mar 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -4,361 -100% $0.000000* 0 16 Mar 2022 Common Stock 4,361 $374.12 Direct F1, F2
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -7,830 -100% $0.000000* 0 17 Mar 2022 Common Stock 7,830 $376.69 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.
F3 The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.